19
Jul
2011
Posted in I - Series B, Q - 2Q11, R - MID WEST, X - Anemia, X - Vascular, XX - OH
Akebia Therapeutics (Cincinnati, OH) a clinical-stage pharmaceutical focused on anemia and vascular disorders, closed a $22M Series B financing. Participants include Novartis Venture Fund, Venture Investors, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners, Sigvion Capital and AgeChem.
15
Sep
2009
Posted in I - Series A, Q - 3Q09, R - MID WEST, X - Anemia, X - Vascular, XX - OH
Akebia Therapeutics (Cincinnati, OH) a clinical-stage biopharmaceutical company focused on the development of small-molecules for anemia and vascular disease, closed a $16M Series A bringing the total financing to $25M. Participants include Novartis Venture Fund, Venture Investors, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners and Sigvion Capital.
09
Jun
2009
Posted in I - Series B, Q - 2Q09, R - NORTH EAST, X - Hemodialysis, X - PAD, X - Renal, X - Vascular, XX - MA
Proteon Therapeutics (Waltham, MA) a clinical-stage biopharmaceutical company focused on a recombinant human elastase designed to improve arteriovenous fistula surgery outcomes in patients requiring chronic hemodialysis, closed on $12M, bringing the total Series B financing to $50M. Participants include Bessemer Venture Partners, Devon Park Bioventures, MPM Bio, Vectis Healthcare & Life Science Fund, TVM Capital, [...]
30
Mar
2009